

March 10, 1965

William C. Janasen, M.D.  
Director of Clinical Research  
Lakeside Laboratories  
1707 E. North Avenue  
Milwaukee 2, Wisconsin

Dear Dr. Janasen:

For a number of years my associate Dr. Itil and I have been interested in Ditrán. Since coming to Missouri, we have carried out a number of investigations, primarily of the effects of Ditrán on the electroencephalogram and on behavior. As you know, Dr. Gershon has carried out detailed behavioral studies as well.

Sometime last year you were kind enough to make available supplies of Ditrán for animal use. At the present time we would like to renew our studies in patients, and would like to request additional supplies. Recognizing the problems of working with an experimental drug such as Ditrán, we have presented our problem to the Pharmacological Committee of this Department. The Committee has agreed to support our study program and has concurred in our filing an IND with the FDA, if that is necessary.

I will be grateful if you would advise me as to the best steps necessary to make supplies of Ditrán available for human use. If an IND is required and we make such an application, would your pharmacological department be willing to make available the information necessary for this form, defining the mode of production of the drug and its pharmacological characteristics?

Any help that you can give us in this endeavor would be appreciated.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:jm  
cc: G.A. Ulett  
T. Itil